FDA approval covers adults and adolescents ≥12 years (≥88 lbs) with moderate-to-severe plaque psoriasis requiring systemic therapy or phototherapy, expanding systemic options beyond injectables.
The FDA has approved the first oral interleukin (IL)-23-targeted therapy for plaque psoriasis, Johnson & Johnson announced.
Adults with moderate to severe plaque psoriasis saw the greatest mean quality-of-life gains with biologic therapy whereas home phototherapy offered lower costs for patients and payers, according to a ...
Each August, Psoriasis Awareness Month shines a light on a condition affecting millions worldwide. This special time helps people understand psoriasis better. It also builds vital support for ...
AbbVie (ABBV) stock dips as BNP warns J&J’s (JNJ) newly FDA-approved plaque psoriasis pill, Icotyde, may challenge its ...
Icotyde is the first targeted oral peptide IL‑23 receptor antagonist, designed to interrupt a core psoriasis inflammatory axis while avoiding injection-based administration typical of IL‑23 biologics.
Everyday Health on MSN
Psoriasis and allergies: What’s the connection?
Learn how psoriasis, allergies, and eczema are connected and how they're different. Get lifestyle tips on managing both.
Psoriasis patients are stigmatized and can later develop debilitating arthritis. July 29, 2011— -- Reality star Kim Kardashian publicly revealed a nasty rash to her dermatologist on a recent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results